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Cyproheptadine hydrochloride (CH) is rarely used to treat adult patients with migraine in Japan because it causes
sleepiness. In this study, we investigated the preventive effect of CH in 12 patients who had failed to respond to
conventional preventive treatments among 103 migraine patients treated at our hospital. These 12 subjects had all
received unsuccessful migraine prophylaxis with lomerizine, valproic acid and topiramate, or had discontinued
these treatments due to adverse reactions. Initially, the subjects were given 4 mg CH before sleeping. In those who
experienced no clinically significant sleepiness following the treatment, the drug was orally administered at 4 mg
after breakfast as well (8 mg per day in total). Drug efficacy was evaluated by examining the frequency of migraine
at one month and three months after the start of treatment. The frequency of migraine was dramatically reduced
in all patients within 7 to 10 days after starting treatment. The average frequency of migraine during the
three-month period was 2.6 episodes per month, representing a significant (p < 0.01) reduction from the
pretreatment frequency of over 10 per month. Our results indicate that CH may be effective as a migraine-
preventive treatment for patients in whom conventional drugs have been ineffective or have caused side effects.
But this study is not a double blind randomized trial, and an open study with no control group.Introduction
In patients who experience frequent migraine attacks,
the risk of rebound headache is quite high, and regard-
less of the efficacy of the rescue medication, there is a
need for preventive therapy (Headache Classification
Committee of the International Headache Society 2004).
Cyproheptadine hydrochloride (CH) is generally used
outside Japan as a migraine preventive treatment in
pediatric patients (Kara 2010), with excellent results.
In Japan, antidepressants, beta-blockers, antiepileptic
agents, calcium antagonists, etc., are the main medica-
tions used to prevent migraine in adults (Pascual 2012;
Tfelt-hansen 2013), and CH is rarely used in adults, be-
cause it causes sleepiness. Consequently, there has been
no report on the effectiveness of this drug in adult pa-
tients with migraine in Japan. Although CH as an anti-
histamine has been largely replaced by nonsedating
compounds, it nevertheless has efficacy in preventing* Correspondence: ookuma@hachioji-hosp.tokai.ac.jp
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in any medium, provided the original work is pmigraine attacks (Rao et al. 2000; Lewis et al. 2004), and
not just in patients whose migraines are worsened or
triggered by underlying allergies. In this study, we inves-
tigated the preventive effect of CH in patients who did
not respond to conventional preventive treatments.
Subjects
The migraine preventive effect of CH was investigated in
12 of 103 migraine patients treated at our hospital.
These 12 subjects (1 men and 11 women, average age 35;
Table 1) had all received unsuccessful migraine prophy-
laxis with lomerizine, valproic acid and topiramate, or
had discontinued such treatments due to adverse reac-
tions or because of possible fetal side effects during
pregnancy. The frequency of their migraine attacks was
10 or more per month. Among these patients, four had
migraine with aura, four had migraine without aura, and
four had menstrual migraine.an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Results of the use of cyproheptadine
hydrochroride for in refractory migraine patients
prophylaxis
n = 12 Dose of cyproheptadine hydrocride
4 mg/day (n = 8) 8 mg/day (n = 4)
Gender male: female 1:7 all female




Frequency of migraine one
month after start of treament
1.6/month 1.2/month
Frequency of migraine three
month after start of treatment
3.1/month 2.1/month
Adverse reactions Body weight 28.6% Body weight 25.0%
Sleepiness 14.3% Sleepiness 50.0%
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CH was orally administered in subjects who had re-
ceived unsuccessful migraine prophylaxis with lomeri-
zine hydrochloride, valproic acid, and topiramate, or
who had encountered side effects with such treatments,
or had contraindications. Because CH may cause sleepi-
ness, CH 4 mg was initially given before sleeping. In
those who experienced no clinically significant sleepiness
following the treatment, the drug was orally adminis-
tered at 4 mg after breakfast as well. Drug efficacy was
evaluated by examining the frequency of migraine at one
month and three months after the start of treatment.
But this study is not a double blind randomized trial,
and an open study with no control group.
Results
The frequency of migraine was dramatically reduced in
all patients within 7 to 10 days after starting treatment.
No migraine attacks were observed in 9 of the 12 pa-
tients during 1 month after starting the drug. In two
other patients, the frequency of monthly migraine
attacks was reduced to 1. The average frequency of mi-
graine attacks during three months was 2.6 times per
month. These results indicate that CH is effective for
preventing migraine. The incidences of adverse reactions
were 60.7% for sleepiness and 30.3% for increased appe-
tite. Sleepiness was alleviated by changing the dose regi-
men to administration of 1 tablet (4 mg) before sleeping.
Weight gain caused by increased appetite did not de-
velop into a problem after subjects were advised to pay
more attention to their diet. The average frequency of
migraine attacks before CH administration was 8.7 times
per month, but this was decreased to 3.1 times per
month at 3 months after the start of treatment in the
group that received 4 mg per day. The average frequency
of migraine attacks before CH administration was 10.6
times per month in the group that received 8 mg perday, but this was decreased to 2.1 times per month after
3 months. Weight gain was similar in both groups, but
sleepiness was more marked in the higher dose group, in
which its incidence reached 50% (Table 1). The results
of the Willcoxon’s signed rank test were as follows. Two
groups had a ρ-value of 0.01, and showed a significantly
greater contribution than the premedication (Figure 1).
Discussion
A double-blind study for the migraine prophylaxis by
propranol and CH is reported. Before (Rao et al. 2000),
but our study, we performed all prophylaxis to the last,
but protective efficacy for the migraine uses CH only to
refractory patients with frequent migraine. Therefore, it
was shown to our study that CH was effective for the
refractory patients with frequent migraine.
Involvement of the trigeminal-vascular system (Mathew
2001; Silberstein 2004) is generally considered the most
likely cause of migraine. According to this theory, release
of serotonin from platelets induces cerebral vasoconstric-
tion and decreases cerebral blood flow, inducing aura,
including scintillating scotomata. Subsequent serotonin
depletion leads to cerebral vasodilatation and stimulation
of the trigeminal nerve, which extends around vessels such
as intracranial large vessels and the dura mater, inducing
neurogenic inflammation and thus triggering migraine
(Ollat 1992; Greek 2006; Hammon & Hoyer 2008). There
are seven types of serotonin receptors. The serotonin 1
and 2 receptors are involved in cerebral vasoconstriction,
and the serotonin 1 receptor exists predominantly in
cerebral blood vessels. Furthermore, several subtypes of
the serotonin 1 receptor have been identified, and among
them, the serotonin 1B and 1D receptors are considered
to be involved in cerebral vasoconstriction and in causing
migraine (Ferrari et al. 2001; Wolff et al. 2003; Filip &
Bader 2009). It has also been shown that binding of sero-
tonin to the serotonin 1D receptor at trigeminal nerve ter-
minals inhibits release of vasoactive peptides, including
calcitonin gene-related peptides.
CH, which we used in this study, is generally used for
migraine in pediatric patients, but not adult patients. In
addition to its antihistaminic action, CH exerts antisero-
tonin and anticholinergic actions, and antagonizes hista-
mine and serotonin receptors. It does not inhibit or
chemically inactivate release of histamine and serotonin,
but competitively and reversibly antagonizes histamine
and serotonin at receptor sites. Therefore, we conclude
that CH showed superior prophylactic efficacy to com-
monly used drugs in our patients owing to its inhibition
of the release of vasoactive peptides, including calcitonin
gene-related peptides, with simultaneous inhibition of
both serotonin 1B and 1D receptors and prevention of
neurogenic inflammation caused by stimulation of the
trigeminal nerve in patients with refractory migraine
Pre-CH         CH           CH
(4 mg/day)    (8 mg /day)
n = 12              n = 8           n = 4


























p < 0.01 : Willcoxon’s signed rank test
*p < 0.01
Figure 1 The results of the Willcoxon’s signed rank test of the use of cyproheptadine hydrochroride.
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with allergic rhinitis and refractory migraine is consid-
ered to be attributable its antihistaminic action.
Based on the present results, we suggest that even
adult patients who do not respond to multiple drugs
currently used for migraine prophylaxis should be given
preventive therapy with CH. However, since the antiser-
otonin action of CH is stronger than that of lysergic acid
diethylamide (LSD), great care is needed to prevent the
onset of visual hallucinations and confusion, especially
at higher doses. Also, weight gain should be anticipated
due to stimulation of the feeding center by the anti-
cholinergic action of this drug. Long-term treatment
with CH should be avoided.
Conclusions
Currently, antidepressants, beta-blockers, antiepileptic
agents, and calcium antagonists are used in Japan to
prevent frequent, intractable migraine in adults. The
results of this study demonstrate that CH is effective asa migraine-preventive treatment for adult Japanese pa-
tients in whom such conventional drugs are ineffective
or induce undesirable side effects.
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